S. Rangarajan

发表

Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

J. Oldenburg, T. Lissitchkov, C. Hay, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Managing the Mature Person with Hemophilia

S. Rangarajan, T. Yee, 2011 .

Clinically significant differences between point-of-care analysers and a standard analyser for monitoring the International Normalized Ratio in oral anticoagulant therapy: a multi-instrument evaluation in a hospital outpatient setting

S. Rangarajan, G. Moore, A. Henley, 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Acquired agranulocytosis and factor XI deficiency in association with thymoma.

S. Rangarajan, P. Fields, Y. Jethava, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real life experiences of a PK dosing study—Challenges and lessons learned.

E. Nielsen, S. Jönsson, P. Collins, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors of coagulation

S. Rangarajan, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open‐label phase 3 trial

E. Santagostino, M. Carcao, S. Rangarajan, 2016, Journal of thrombosis and haemostasis : JTH.

Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma

S. Rangarajan, M. Mitchell, B. Sørensen, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic and pharmacodynamic properties of plasma‐derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study

S. Rangarajan, B. Sørensen, J. Alamelu, 2014, Journal of thrombosis and haemostasis : JTH.

The clinical implications of ADAMTS13 function: the perspectives of haemostaseologists.

C. Kessler, L. Aledort, S. Rangarajan, 2013, Thrombosis Research.

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

A. Akinc, D. Bevan, K. Pasi, 2017, The New England journal of medicine.

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A

J. Oldenburg, J. Mahlangu, R. Klamroth, 2016, Thrombosis and Haemostasis.

Multitypic Hepatitis C Virus Infection Identified by Real-Time Nucleotide Sequencing of Minority Genotypes

C. Arnold, P. Klapper, M. Ramsay, 2006, Journal of Clinical Microbiology.

Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.

K. Fischer, J. Mahlangu, B. Nolan, 2017, The Lancet. Haematology.

Adeno-associated virus (AAV)–mediated gene therapy is under investigation as a thera- peutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ

M. Laffan, K. Pasi, S. Rangarajan, 2019 .

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

R. Liesner, D. Hart, P. Collins, 2013, British journal of haematology.

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

R. Liesner, D. Hart, B. Palmer, 2014, Blood.

Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO

R. Liesner, D. Hart, S. Rangarajan, 2013, British journal of haematology.

Low frequency of elevated prothrombin times in patients with lupus anticoagulants when using a recombinant thromboplastin reagent: implications for dosing and monitoring of oral anticoagulant therapy

S. Rangarajan, G. Moore, A. Henley, 2005, British journal of biomedical science.

Purple toe syndrome following anticoagulant therapy

S. Rangarajan, K. Raj, B. Collins, 2001, British journal of haematology.

AAV5–Factor VIII Gene Transfer in Severe Hemophilia A

D. Perry, M. Laffan, S. Rangarajan, 2017, The New England journal of medicine.

Activity of Transgene-Produced B-Domain Deleted Factor VIII in Human Plasma Following AAV5 Gene Therapy.

K. Pasi, S. Rangarajan, G. Pierce, 2020, Blood.

Erythrocyte folate and 5-methyltetrahydrofolate levels decline during 6 months of oral anticoagulation with warfarin

M. Shearer, M. Lomer, S. Rangarajan, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Fibrinogen concentrate for acquired hypofibrinogenaemic states

S. Rangarajan, R. Weinkove, 2008, Transfusion medicine.

The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial

P. Arkhammar, J. Mahlangu, S. Rangarajan, 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Management of haemophilia A with inhibitors: A regional cross‐talk

A. El‐Beshlawy, F. Peyvandi, S. Rangarajan, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of recombinant factor VIIa for post‐operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies

S. Rangarajan, R. Patel, G. Savidge, 2001, British journal of haematology.

Diagnosis and management of acquired coagulation inhibitors : a guideline from UKHCDO A United Kingdom Haemophilia Centre Doctors ’ Organization ( UKHCDO ) guideline approved by the British Committee for Standards in Haematology

R. Liesner, D. Hart, P. Collins, 2013 .

Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei

C. Solomon, S. Knaub, S. Rangarajan, 2019, Journal of thrombosis and haemostasis : JTH.

Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A

D. Perry, S. Fong, S. Rangarajan, 2019, Research and practice in thrombosis and haemostasis.

Fibrinogen estimates are influenced by methods of measurement and hemodilution with colloid plasma expanders

S. Rangarajan, J. Ingerslev, B. Sørensen, 2010, Transfusion.

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)

S. Robson, V. Jiménez‐Yuste, M. Ozelo, 2022, Research and practice in thrombosis and haemostasis.

Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors

S. Rangarajan, T. Yee, J. Wilde, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Von Willebrand factor – two sides and the edge of a coin

S. Rangarajan, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non‐orthopaedic surgery

C. Négrier, E. Rodríguez‐Merchán, N. Goddard, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

M. Laffan, K. Pasi, S. Rangarajan, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom.

R. Liesner, B. Palmer, P. Collins, 2011, Blood.

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates

A. Iorio, M. Morfini, V. Blanchette, 2017, Thrombosis and Haemostasis.

Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort

M. Laffan, S. Rangarajan, N. Curry, 2022, Research and practice in thrombosis and haemostasis.

The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

K. Pasi, P. Collins, S. Rangarajan, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factor VIII: a prospective cohort comparison

R. Liesner, D. Hart, B. Palmer, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Michael Recht, Pratima Chowdary, Deepak Raj, 2014, The New England journal of medicine.

Clinical haemophilia Long-term safety and efficacy of recombinant factor VIII Fc fusion protein ( rFVIIIFc ) in subjects with haemophilia

D. Perry, B. Konkle, K. Pasi, 2016 .

Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study

D. Perry, B. Konkle, J. Mahlangu, 2015 .

Will gene therapy trump factor treatment in hemophilia?

L. Aledort, S. Rangarajan, 2013, Expert review of hematology.

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India

S. Apte, S. Rangarajan, M. John, 2022, Indian Journal of Hematology and Blood Transfusion.

Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrate

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2019, Haemophilia.

Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures

C. Kessler, A. Klukowska, N. Zozulya, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Pratima Chowdary, Savita Rangarajan, Cecilia Rosales, 2011, The New England journal of medicine.

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.

M. Laffan, K. Pasi, S. Rangarajan, 2020, The New England journal of medicine.

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

D. Perry, B. Konkle, K. Pasi, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

L. Frenzel, O. Stasyshyn, S. Pipe, 2021, Blood.

Low‐dose prophylaxis and its impact on the health of haemophilia patients

S. Bansal, S. Rangarajan, S. Shetty, 2022, Vox sanguinis.

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non‐severe haemophilia A

K. Khair, P. Batty, D. Hart, 2017, British journal of haematology.

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

A. Akinc, D. Bevan, K. Pasi, 2015 .

Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies

V. Jiménez‐Yuste, K. Khair, F. Smiers, 2015, Thrombosis and Haemostasis.

Haemophilia: A race for cure

L. Aledort, S. Rangarajan, Rea Cj, 2017 .

First‐line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

M. Makris, R. Liesner, D. Hart, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product

V. Jiménez‐Yuste, E. Santagostino, S. Rangarajan, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical overview of Fanhdi/Alphanate (plasma‐derived, VWF‐containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A

K. Pasi, P. Batty, D. Hart, 2015, Thrombosis and Haemostasis.

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A

S. Bunting, K. Pasi, S. Fong, 2022, Nature Medicine.

Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors

S. Robson, V. Jiménez‐Yuste, M. Ozelo, 2021, 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research.

Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full‐length FVIII treatment to B‐domain‐deleted r‐FVIII and back to full‐length FVIII

S. Rangarajan, C. Rea, B. Sørensen, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B

Creagh, A. Akinc, D. Bevan, 2016 .

Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients

E. Santagostino, M. Carcao, S. Rangarajan, 2014 .

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India

S. Apte, S. Rangarajan, M. John, 2022, Indian Journal of Hematology and Blood Transfusion.

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.

M. Laffan, K. Pasi, S. Rangarajan, 2020 .

Malignant sarcoma masquerading as a pseudotumour in a patient with mild haemophilia

S. Rangarajan, B. Cheung, P. Connor, 2003, British journal of haematology.

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

D. Perry, B. Konkle, K. Pasi, 2015 .

A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERAPEUTIC EFFICACY AND SAFETY OF AAV GENE THERAPY WITH VALOCTOCOGENE ROXAPARVOVEC FOR SEVERE HEMOPHILIA A

M. Ozelo, M. Laffan, K. Pasi, 2020 .

Incidental finding of Hodgkin’s disease following initial presentation with traumatic haematoma in the thoracic inlet

S. Rangarajan, B. Marson, M. Smith, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

A. Akinc, D. Bevan, K. Pasi, 2016 .

Further evidence of false negative screening for lupus anticoagulants.

S. Rangarajan, G. Moore, A. Henley, 2008, Thrombosis research.

Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19

M. Laffan, Ahilanandan Dushianthan, A. Mumford, 2021, Thrombosis Research.

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

F. Peyvandi, T. Lissitchkov, S. Apte, 2018, Journal of thrombosis and haemostasis : JTH.

COVID‐19 and preeclampsia: The unique and the mutually nonexclusive clinical manifestations

S. Bansal, S. Rangarajan, S. Shetty, 2023, American journal of reproductive immunology.

Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy.

S. Rangarajan, R. Kulasegaram, J. van der Walt, 2005, AIDS.

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.

L. Frenzel, O. Stasyshyn, S. Pipe, 2023, The Lancet. Haematology.

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

G. Young, S. Rangarajan, C. Ross, 2023, The Lancet.

Three dominant‐negative mutations in factor XI‐deficient patients

S. Rangarajan, M. Mitchell, L. Dai, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies

S. Rangarajan, G. Moore, G. Savidge, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)

R. Wu, G. Young, S. Rangarajan, 2021, Blood.

The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders

V. Jiménez‐Yuste, R. Kruse-Jarres, C. Altisent, 2016, Thrombosis and Haemostasis.

A study of the prevalence of vitamin K deficiency in patients with cancer referred to a hospital palliative care team and its association with abnormal haemostasis

M. Shearer, S. Rangarajan, D. Harrington, 2007, Journal of Clinical Pathology.

RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection

S. Rangarajan, S. Boyce, 2023, Journal of blood medicine.

A national survey of immunosuppression strategies for acquired haemophilia A

R. Liesner, P. Batty, D. Hart, 2015, Haemophilia.

Hyperhomocysteinemia and B-Vitamin Status after Discontinuation of Oral Anticoagulation Therapy in Patients with a History of Venous Thromboembolism

M. Shearer, S. Rangarajan, G. Savidge, 2003, Clinical chemistry and laboratory medicine.

Prognostic model to predict postoperative acute kidney injury in patients undergoing major gastrointestinal surgery based on a national prospective observational cohort study

A. Sales, T. Rockall, H. Khan, 2018, BJS open.

Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India

K. Cornetta, J. Mahlangu, S. Rangarajan, 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

Challenges of one-year longitudinal follow-up of a prospective, observational cohort study using an anonymised database: recommendations for trainee research collaboratives

A. Sales, T. Rockall, H. Khan, 2019, BMC medical research methodology.

Predictive Role of Haematological Determinants on Outcomes of Critically Ill COVID-19 Patients Admitted to Intensive Care Unit

Ahilanandan Dushianthan, S. Rangarajan, R. Kazmi, 2021, Cureus.

S. Rangarajan, M. Mitchell, G. Savidge, 2003, British journal of haematology.

Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-alpha 2b and ribavirin.

S. Rangarajan, C. Teo, R. Kulasegaram, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin's lymphoma.

R. Carr, S. Rangarajan, G. Moore, 2004, Clinical and laboratory haematology.

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

J. Esser, G. Tiscia, M. N. D. Minno, 2012, Journal of thrombosis and haemostasis : JTH.

Achievement of Normal Circulating Factor VIII Activity Following Bmn 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia a

D. Perry, K. Pasi, S. Rangarajan, 2017 .

First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Α

B. Konkle, A. Shapiro, W. Miesbach, 2020 .

Molecular characterization of 11 novel mutations in patients with heterozygous and homozygous FV deficiency

S. Rangarajan, M. Mitchell, R. Tait, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

M. Kay, A. Nienhuis, J. Gray, 2014, The New England journal of medicine.

Erythrocyte folate and 5-methyltetrahydrofolate levels decline during 6 months of oral anticoagulation with warfarin

M. Shearer, M. Lomer, S. Rangarajan, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Fibrinogen Concentrate vs Cryoprecipitate in Pseudomyxoma Peritonei Surgery: Interim Results from a Prospective, Randomized, Controlled Phase 2 Study

S. Knaub, S. Rangarajan, F. Mohamed, 2018, Hämostaseologie.

Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India

K. Fischer, S. Rangarajan, S. Shetty, 2023, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies

V. Jiménez‐Yuste, K. Khair, F. Smiers, 2015, Thrombosis and Haemostasis.